Clinical Efficacy and Safety of Salvianolate Combined with Dual Antiplate-let Therapy for Acute Non-cardiogenic Non-massive Cerebral Infarction

MENG Xiaomin; TIAN Li; JIA Qiang; GUO Zhili

doi:10.3969/j.issn.1002-3429.2024.06.017

Abstract：Objective To explore the clinical efficacy and safety of Salvianolate(SAL)combined with dual anti-platelet therapy in the treatment of acute non-cardiogenic non-massive cerebral infarction.Methods Sixty patients with acute non-cardiogenic non-massive cerebral infarction treated from February 2022 to March 2023 were randomly divided into two groups,with 30 cases in each group,by random number table method.The control group was treated with dual antiplatelet therapy,and the observation group was treated with SAL for injection combined with dual antiplatelet therapy.The clinical ef-ficacy and adverse reactions of the two groups were observed.Fibrinogen(FIB),prothrombin time(PT),homocysteine(Hcy),soluble apoptosis-related factor ligand(sFasL),anti-apoptosis-related factor(Livin),soluble apoptosis-related factor(sFas),cerebral blood perfusion,Kelch-like epichloropropylamine associated protein 1(Keap1)-nuclear factor E2 associated factor2(Nrf2)/antioxidant component(ARE)signaling pathway[Keap1,Nrf2,quinone oxidoreductase(NQO1),ARE]protein expression,National Institutes of Health Stroke Scale(NIHSS)score,and Modified Rankin Scale(mRS)score before and after treatment were observed.Results The total effective rate of observation group was 93.33%(28/30),which was higher than that of control group[73.33%(22/30)](P＜0.05).At 1 and 2 weeks after treatment,the expression of FIB,Hcy,sFas,sFasL and Keap1 protein in observation group was lower than that in control group,the PT was longer than that in control group,the expression of Nrf2,NQO1,ARE protein and Livin level were higher than that in control group,and the blood flow velocity of anterior cerebral artery,middle artery and posterior artery was greater than that in control group(P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).At 2 weeks and 3 months after treatment,mRS And NIHSS scores in the observation group were lower than those in the control group(P＜0.05).Conclusion SAL combined with dual antiplatelet therapy is effective in the treatment of acute non-cardiogenic non-massive cerebral infarction,and can improve nerve function and prognosis by regulating coagulation function,cerebral microcirculation,and Keap1-Nrf2/ARE signaling pathway,with certain safety.